CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that it was notified by one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), that preliminary data with a protein agonist of the Sonic Hedgehog (Shh) signaling pathway showed promising results in an established, early preclinical cardiovascular animal model. These positive results are consistent with previously published third-party data in which upregulation of the Shh pathway were demonstrated to be efficacious. Research using Shh protein agonists in various cardiovascular disease models is ongoing at Wyeth.
